Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

Interview

Isatuximab Plus Carfilzomib and Dexamethasone Improves PFS in Multiple Myeloma

Marcelo Capra, MD, Centro de Hematologia e Oncologia, Hospital Mãe de Deus, Porto Alegre, Brazil, discusses results from a study comparing the benefit of progression-free survival associated with isatuximab in combination with carfilzomib and dexamethasone vs carfilzomib and dexamethasone among patients with relapsed/refractory multiple myeloma previously treated with one to three lines of therapy.

Advertisement

Advertisement

Advertisement